HILOPRO® enables high-dose, large molecule monoclonal antibodies to move from IV administration to subcutaneous injection. Using only two GRAS excipients, HILOPRO® delivers low-volume formulations with concentrations greater than 250mg/mL, while maintaining a viscosity less than 20 cP. Naturally, this introduces tremendous patient benefits in terms of comfort and convenience and enables innovator and biosimilar mAbs to enhance their marketability.